Investors seeking momentum may have iShares U.S. Pharmaceuticals ETF IHE on radar now. The fund recently hit a new 52-week high. Shares of IHE are up approximately 29.6% from their 52-week low of $58.

Fintel reports that on November 5, 2025, Citizens maintained coverage of BioCryst Pharmaceuticals (NasdaqGS:BCRX) with a ...

Revenue climbed 8.6% to Rs 14,405.2 crore, driven by double-digit growth in India, emerging markets, and rest of world (RoW) ...

Sun Pharma Executive Chairman Dilip Shanghvi said the company remains on track to launch UNLOXCYT, an FDA-approved treatment ...

So, if you're able to regularly invest in the Vanguard fund for many years, history offers us reason to be optimistic about ...

Speculative activity surged across the micro-cap landscape during the third quarter, fueled by thematic momentum and outsized ...

Indian private equity firm, ChrysCapital, has successfully raised a record $2.2 billion for its latest fund, ChrysCapital X, ...

London-listed Haleon, a consumer healthcare company, and medical devices maker Smith & Nephew confirmed they too have removed ...

The top management has expressed confidence in its investment pipeline, with a sustained focus on making investments into ...

The latest investment brings the British pharma’s total investment at the site in Qingdao to $886 million. AstraZeneca ...

Forbion BioEconomy Fund I reaches hard cap, following its first close in 2024.The Fund's planetary health mandate leverages Forbion’s extensive biotech know-how and expertise in human health.Fund to ...

Bloomington and IU Columbus did their best to look into a crystal ball to predict economic conditions locally, statewide, and for the United States in 2026 during a panel Wednesday.